Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
作者信息
Penson David F, Armstrong Andrew J, Concepcion Raoul S, Agarwal Neeraj, Olsson Carl A, Karsh Lawrence I, Dunshee Curtis J, Duggan William, Shen Qi, Sugg Jennifer, Haas Gabriel P, Higano Celestia S
机构信息
Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.
Division of Medical Oncology, Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.
出版信息
Prostate Cancer Prostatic Dis. 2022 Sep;25(3):597. doi: 10.1038/s41391-021-00477-3.
Abstract
摘要
相似文献
1
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.更正：恩杂鲁胺对比比卡鲁胺治疗非转移性去势抵抗性前列腺癌患者：STRIVE试验的一项预设亚组分析。
Prostate Cancer Prostatic Dis. 2022 Sep;25(3):597. doi: 10.1038/s41391-021-00477-3.
2
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.恩杂鲁胺对比比卡鲁胺用于治疗非转移性去势抵抗性前列腺癌患者：STRIVE 试验的预先设定亚组分析。
Prostate Cancer Prostatic Dis. 2022 Feb;25(2):363-365. doi: 10.1038/s41391-021-00465-7. Epub 2021 Oct 7.
3
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.恩杂鲁胺对比比卡鲁胺用于去势抵抗性前列腺癌：STRIVE 试验。
J Clin Oncol. 2016 Jun 20;34(18):2098-106. doi: 10.1200/JCO.2015.64.9285. Epub 2016 Jan 25.
4
Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.在TERRAIN试验中恩杂鲁胺与比卡鲁胺治疗年轻和老年转移性去势抵抗性前列腺癌患者的疗效与安全性
J Urol. 2018 Jan;199(1):147-154. doi: 10.1016/j.juro.2017.08.080. Epub 2017 Aug 19.
5
Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial.恩杂鲁胺对比比卡鲁胺对转移性去势抵抗性前列腺癌患者生活质量的影响：来自 TERRAIN 随机临床试验的附加分析。
Eur Urol. 2017 Apr;71(4):534-542. doi: 10.1016/j.eururo.2016.07.027. Epub 2016 Aug 3.
6
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.恩杂鲁胺治疗去势抵抗性前列腺癌非转移性患者的疗效。
N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.
7
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.恩扎卢胺对比比卡鲁胺用于转移性前列腺癌患者的疗效和安全性（TERRAIN）：一项随机、双盲、2 期研究。
Lancet Oncol. 2016 Feb;17(2):153-163. doi: 10.1016/S1470-2045(15)00518-5. Epub 2016 Jan 14.
8
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study.比卡鲁胺联合雄激素阻断治疗后恩扎卢胺对比氟他胺治疗去势抵抗性前列腺癌：OCUU-CRPC 研究。
Int J Clin Oncol. 2020 Mar;25(3):486-494. doi: 10.1007/s10147-019-01554-3. Epub 2019 Sep 28.
9
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).比卡鲁胺联合雄激素阻断治疗后恩扎卢胺对比氟他胺治疗去势抵抗性前列腺癌的多中心随机 II 期临床试验研究方案（OCUU-CRPC 研究）
BMC Cancer. 2019 Apr 11;19(1):339. doi: 10.1186/s12885-019-5526-3.
10
Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.达罗他胺对比阿帕他胺和恩扎卢胺用于去势抵抗性前列腺癌的间接比较。
J Urol. 2021 Aug;206(2):298-307. doi: 10.1097/JU.0000000000001767. Epub 2021 Apr 5.
引用本文的文献
1
Targeting CDK7 enhances the antitumor efficacy of enzalutamide in androgen receptor-positive triple-negative breast cancer by inhibiting c-MYC-mediated tumorigenesis.靶向CDK7通过抑制c-MYC介导的肿瘤发生增强恩杂鲁胺在雄激素受体阳性三阴性乳腺癌中的抗肿瘤疗效。
Mol Cancer Ther. 2024 Nov 26. doi: 10.1158/1535-7163.MCT-23-0386.
2
Breast Cancer Treatment: To tARget or Not? That Is the Question.乳腺癌治疗：靶向与否？这是个问题。
Cancers (Basel). 2023 Nov 30;15(23):5664. doi: 10.3390/cancers15235664.
Zotero 插件